Becoming a Force in Digital Health.
RF Health Press/News
Recovery Force Health to Commercially Launch Movement And Compressions at NTI 2022
Recovery Force Health’s Mobility Measurement device provides therapeutic compressions to prevent DVT. Meet the MAC System.
Recovery Force Presents At The 2021 American Heart Association’s Scientific Sessions
Recovery Force, LLC has been selected for a showcase presentation during the 2021 American Heart Association Annual (Virtual) Scientific Sessions, the world-leading annual event for researchers, medical and healthcare professionals in science, prevention, and treatment of cardiovascular pathologies.
Recovery Force ISO 13485 Certification
ISO 13485, Medical devices – Quality Management Systems – requirements for regulatory purposes, is an internationally recognized standard for organizations involved in the medical device industry. Companies are using compliance to this standard to obtain the certification of their Quality Management System. The primary purpose of the ISO 13485 standard is the Harmonization of the Medical Device regulatory requirements for Quality Management Systems.
Company Awards / Achievements
-
National Institutes of Health - Phase I Award
Small Business Innovative Research (SBIR) $300k Innovation Grant
Initial funding supports the development of wearable technology to reduce the risk of DVT and increase patient compliance.
-
National Institutes of Health - Phase II Award
Small Business Innovative Research (SBIR) $1.8M Innovation Grant
Validation of wearable technology to reduce the risk of DVT and optimize mobility measurement.
-
Top Cardiac and Vascular Disorder Startup 2021
The Cardiac and Vascular Disorders has over 2.2K+ startups that comprise of companies that engaged in R&D for developing medical devices, diagnostics tests, and pharmaceuticals for the diagnosis and treatment of cardiac and vascular disorders.
Recovery Force made a curated list of the most promising startups leading the Cardiac and Vascular Disorders industry, from across the globe.
+ Disclaimer/Acknowledgement
Research reported in this presentation was supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Numbers R43HL132624 & R44HL132624. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Grant number R43HL132624 financed jointly with 83 percent government ($244,167) and non-governement ($50,000) funding. Grant number R44HL132624 financed with 100 percent government ($1,763,777) funding.